Styrylquinoline derivatives: A new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells

Journal of Medicinal Chemistry

Volumn 41, Issue 15, 1998, Pages 2846-2857

  Mekouar, Khalid ^a   Mouscadet, Jean François ^b   Desmaële, Didier ^a   Subra, Frédéric ^b   Leh, Hervé ^b   Savouré, Delphine ^b   Auclair, Christian ^b   D'Angelo, Jean ^a  

^a UNIVERSITÉ PARIS SUD   (France)

^b PRII   (France)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXY 2 [2 (3 CARBOXYL 4 HYDROXYPHENYL) 7 QUINOLINE CARBOXYLIC ACID; INTEGRASE INHIBITOR; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CRYSTALLIZATION; DNA INTEGRATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIGAND BINDING; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE, TRANSFORMED; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MUTATION; QUINOLINES; SEQUENCE DELETION; STYRENES; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0031875905     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980043e     Document Type: Article

References (59)

1. Ho, D. D.; Neumann, A. U.; Perelson, A. S.; Chen, W.; Leonard, J. M.; Markowitz, M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373, 123-126.
2. De Clercq, E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infection. J. Med. Chem. 1995, 38, 2491-2517.
3. Lafemina, R. L.; Schneider, C. L.; Robhins, H. L.; Callahan, P. L.; Legrow, K.; Roth, E.; Schleif, W. A.; Emini, E. A. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J. Virol. 1992, 66, 7414-7419.
4. Brown, P. O. Integration of reroviral DNA. Curr. Top. Mirrobiol. Immunol. 1990, 157, 19-48.
5. Craigie. R.; Mizuuchi, K.; Bushman, F. D.; Engelman, A. A rapid in vitro assay for HIV DNA integration. Nucleic Acids Res. 1991, 19, 2729-2734.
6. Chow, S. A.; Vincent, K. A.; Ellison, V.; Brown, P. O. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science 1992, 255, 723-726.
7. Chow, S. A.; Brown, P. O. Substrate features important for recognition and catalysis by human immunodeficiency virus type 1 integrase identified by using novel DNA substrates. J. Virol. 1994, 68, 3896-3907.
8. Carteau, S.; Mouscadet, J. F.; Goulaouic, H.; Subra, F.; Auclair, C. Effect of topoisomerase inhibitors on the in vitro HIV DNA integration reaction. Biochem. Biophys. Res. Commun. 1993, 192, 1409-1414.
9. Fesen, M. R.; Kohn, K. W.; Leteurtre, F.; Pommier, Y. Inhibitors of human immunodeficiency virus integrase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 2399-2403.
10. Mouscadet, J. F.; Carteau, S.; Goulaouic, H.; Subra, F.; Auclair, C. Triplex-mediated inhibition of HIV DNA integration in vitro. J. Biol. Chem. 1994, 269, 21635-21638.
11. Bouziane, M.; Cherny, D. L; Mouscadet, J. F.; Auclair, C. Alternate strand DNA triple helix-mediated inhibition of HIV-1 U5 long terminal repeat integration in vitro. J. Biol. Chem. 1996, 271, 10359-10364.
12. Carteau, S.; Mouscadet, J. F.; Goulaouic, H.; Subra, F.; Auclair, C. Inhibitory effect of the polyanionic drug suramin in the in vitro HIV DNA integration reaction. Arch. Biochem. Biophys. 1993, 305, 606-610.
13. Cushman, M.; Sherman, P. Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogues, and polymer fractions. Biochem. Biophys. Res. Commun. 1992, 185, 85-90.
14. LaFemina, R. L.; Graham, P. L.; LeGrow, K.; Hastings, J. C.; Wolfe, A.; Young, S. D.; Emini, E. A.; Hazuda, D. J. Inhibition of human immunodeficiency virus integrase by bis-catechols. Antimicrob. Agents Chemother. 1995, 39, 320-324.
15. Fesen, M. R.; Pommier, Y.; Leteurtre, F.; Hiroguchi, S.; Yung, J.; Kohn, K. W. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem. Pharmacol. 1994, 48, 595-608.
16. Mazumder, A.; Raghavan, K.; Weinstein, J.; Kohn, K. W.; Pommier, Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem. Pharmacol. 1995, 49, 1165-1170.
17. Mazumder, A.; Gazit, A.; Levitzki, A.; Nicklaus, M.; Yung, J.; Kohlhagen, G.; Pommier, Y. Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. Biochemistry 1995, 34, 15111-15122.
18. Eich, E.; Pertz, H.; Kaloga, M.; Schulz, J.; Fesen, M. R.; Mazumder, A.; Pommier. Y. (-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase. J. Med. Chem. 1996, 39, 86-95.
19. Zhao, H.; Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Milne, G. W. A.; Pommier, Y.; Burke, T. R., Jr. Coumarin-based inhibitors of HIV integrase. J. Med. Chem. 1997, 40, 242-249.
20. Cushman, M.; Golebiewski, W. M.; Pommier, Y.; Mazumder, A.; Reymen, D.; de Clercq, E.; Graham, L.; Rice, W. G. Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase. J. Med. Chem. 1995, 38, 443-452.
21. Zhao, H.; Neamati, N.; Sunder, S.; Hong, H.; Wang, S.; Milne, G. W. A.; Pommier, Y.; Burke, T. R., Jr. Hydrazide-containing inhibitors of HIV-1 integrase. J. Med. Chem. 1997, 40, 937-941.
22. Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Nicklaus, M. C.; Milne. G. W. A.; Proksa, B.; Pommier, Y. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. J. Med. Chem. 1997, 40, 942-951.
23. Neamati, N.; Mazumder, A.; Zhao, H.; Sunder, S.; Burke, T. R., Jr.; Schultz, R. J.; Pommier, Y. Diaryl sulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors. Antimicrob. Agents Chemother. 1997, 41, 385-393.
24. Hong, H.; Neamati, N.; Wang, S.; Nicklaus, M.; Mazumder, A.; Zhao, H.; Burke, T. R., Jr.; Pommier, Y.; Milne, G. W. A. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 1997, 40, 930-936.
25. Nicklaus, M.; Neamati, N.; Hong, H.; Mazumder, A.; Sunder, S.; Chen, J.; Milne, G. W. A.; Pommier, Y. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 1997, 40, 920-929.
26. Raghavan, K.; Buolamwini, J. K.; Fesen, M. R.; Pommier, Y.; Kohn, K. W.; Weinstein, J. N. Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study. J. Med. Chem. 1997, 38, 890-897.
27. Buolamwini, J. K.; Raghavan, K.; Fesen, M. R.; Pommier, Y.; Kohn, K. W.; Weinstein, J. N. Application of the electrotopological state index to QSAR analysis of flavone derivatives as HFV-I integrase inhibitors. Pharm. Res. 1996, 13, 1892-1895.
28. Sourgen, F.; Maroun, R. G.; Frere, V.; Bouziane, M.; Auclair, C., Troalen, F.; Fermandjian, S. A synthetic peptide from the human immunodeficiency virus type-1 integrase exhibits coiled-coil properties and interferes with the in vitro integration activity of the enzyme. Correlated biochemical and spectroscopic results. Eur. J. Biochem. 1996, 240, 765-773.
29. Puras Lutzke, R. A.; Eppens, N. A.; Weber, P. A.; Houghten, R. A.; Plasterk, R. H. Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 11456-11460.
30. Robinson, W. E., Jr.; Cordeiro, M.; Abdel-Malek, S.; Jia, Q.; Chow, S. A.; Reinecke, M. G.; Mitchell, W. M. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol. Pharmacol. 1996, 50, 846-855.
31. Robinson, W. E., Jr.; Reinecke, M. G.; Abdel-Malek, S.; Jia, Q.; Chow, S. A. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 6326-6331.
32. Mazumder, A.; Neamati, N.; Sommadossi, J.-P.; Gosselin, G.; Schinazi, R. F.; Imbach, J.-L.; Pommier, Y. Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase. Mol. Pharmacol. 1996, 49, 621-628.
33. Mazumder, A.; Neamati, N.; Ojwang, J. O.; Sunder, S.; Rando, R. F.; Pommier, Y. Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry 1996, 35, 13762-13771.
34. Ojwang, J. O.; Buckheit, R. W.; Pommier, Y.; Mazumder, A.; de Vreese, K.; Este, J. A.; Reymen, D.; Pallansch, L. A.; Lackman-Smith, C.; Wallace, T. L. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1995, 39, 2426-2435.
35. Thomas, M.; Brady, L. HIV integrase: a target for AIDS therapeutics. TIBTECH 1997, 15, 167-172.
36. Brown, P. O.; Bowerman, B.; Varmus, H. E.; Bishop, J. M. Correct integration of retroviral DNA in vitro. Cell 1987, 49, 347-356.
37. Ellison, V.; Abrams, H.; Roe, T.; Lifson, J.; Brown, P. Human immunodeficiency virus integration in a cell-free system. J. Virol. 1990, 64, 2711-2715.
38. 2+-dependent 3′-processing activity for human immunodeficiency virus type 1 integrase in vitro: real-time kinetic studies using fluorescence resonance energy transfer. Biochemistry 1995, 34, 10205-10214.
39. Bujacz, G.; Alexandratos, J.; Zhou-Liu, Q.; Clément-Mella, C.; Wlodawer, A. The catalytic domain of human immunodeficiency virus integrase: ordered active site in the F185H mutant. FEBS Lett. 1996, 398, 175-178.
40. Zheng, R.; Jenkins, T. M.; Craigie, R. Zinc folds the N-terminal domain of HIV-I integrase, promotes multimerization, and enhances catalytic activity. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 13659-13664.
41. Katayanagi, K.; Miyagawa, M.; Matsushima, M.; Ishikawa, M.; Kanaya, S.; Ikehara, M.; Matsuzaki, T.; Morikawa, K. Three-dimensional structure of ribonuclease H from E. coli. Nature 1990, 347, 306-309.
42. Davies J. F.; Hostomska, Z.; Jordan, S. R.; Matthews, D. A. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 1991, 252, 88-95.
43. Beese, L. S.; Steitz, T. A. Structural basis for the 3′-5′ exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. EMBO J. 1991, 10, 25-33.
44. Katayanagi, K.; Miyagawa, M.; Matsushima, M.; Ishikawa, M.; Kanaya, S.; Nakamura, H.; Ikehara, M.; Matsuzaki, T.; Morikawa, K. Stutural details of ribonuclease H from Escherichia coli as refined to an atomic resolution. J. Mol. Biol. 1992, 223, 1029-1052.
45. Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Engelman, A.; Craigie, R.; Davies, D. R. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994, 266, 1981-1986.
46. Bujacz, G.; Jaskolski, M.; Alexandratos, J.; Wlodawer, A.; Merkel, G.; Katz, R. A.; Skalka, A. M. The catalytic domain of avian sarcoma virus integrase: conformation of the active-site residues in the presence of divalent cations. Structure 1996, 4, 89-96.
47. Lurik, B. B.; Volkof, Y. P. Insecticide synergists. Chloromethylation of safrole. Zh. Org. Khim. 1986, 22, 384-387.
48. Meek, W. H.; Fuschman, C. H. J. Carboxylation of substituted phenols in N,N-dimethylamide solvents at atmospheric presssure. J. Chem. Eng. Data 1969, 14, 388-391.
49. Irving, H.; Pinnington, A. R. 8-Hydroxyquinaldic acid. J. Chem. Soc. 1954, 3782-3785.
50. Hata, T.; Uno, T. Studies on new derivatives of 8-quinolinol as chelating agents. I. Syntheses, coloration reaction with metal ions and acid dissociation constants of some azomethine and aminomethyl derivatives. Bull. Chem. Soc. Jpn. 1972, 45, 477-481.
51. Przystal, F.; Phillips, J. P. 7-Formyl-8-quinolinols. J. Heterocyl. Chem. 1967, 4, 131-132.
52. Carteau, S.; Mouscadet, J. F.; Goulaouic, H.; Subra, F.; Auclair, C. Quantitative in vitro assay for human immunodeficiency virus deoxyribonucleic acid integration. Arch. Biochem. Biophys. 1993, 300, 756-610.
53. Neamati, N.; Hong, H.; Sunder, S.; Milne, G. W. A.; Pommier, Y. Potent inhibitors of human immunodeficiency virus type 1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol. Pharmacol. 1997, 52, 1041-1055.
54. Buschman, F. D.; Engelman, A.; Palmer, I.; Wingfield, P.; Craigie, R. Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 3428-3432.
55. Jenkins, T. M.; Hickman, A. B.; Dyda, F.; Ghirlando, R.; Davies, D. R.; Craigie, R. Catalytic domain of human immunodeficiency virus type 1 integrase: identification of a soluble mutant by systematic replacement of hydrophobic residues. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 6057-6061.
56. Venclovas, C.; Siksnys, V. Different enzymes with similar structures involved in Mg (2+)-mediated polynucleotidyl transfer. Nature Struct. Bid. 1995, 2, 838-841.
57. Hazuda, D. J.; Felock, P. J.; Hastings, J. C.; Pramanik, B.; Wolfe, A. L. Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase. J. Virol. 1997, 71, 7005-7011.
58. Hansen, M. S.; Bushman, F. D. Human immunodeficiency virus type 2 preintegration complexes: activities in vitro and response to inhibitors. J. Virol. 1997, 71, 3351-3356.
59. 2+-dependent DNA integration in vitro. J. Virol. 1997, 71, 6225-6229.